C.-K. Chris Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
C.-K. Chris Wang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Bo Liu
Department of Radiation Oncology, District Hospital of Changzhi City, Shanxi, People's Republic of China
3 shared publicationsHuiming Liu
Department of Radiation Oncology, District Hospital of Changzhi City, Shanxi, People's Republic of China
3 shared publicationsQifeng Wang
Department of Radiation Oncology, District Hospital of Changzhi City, Shanxi, People's Republic of China
3 shared publicationsXin Zhang
2 shared publicationsXitang Jia
Department of Radiation Oncology, District Hospital of Changzhi City, Shanxi, People's Republic of China
2 shared publications- Xitang Jia
Department of Radiation Oncology, Changzhi Cancer Hospital, Changzhi, Shanxi, 046000, P.R. China.
2 shared publications
Latest Publications
- Open Access
- 13 May 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (10)
Efficient cell-by-cell simulation of DNA double strand breaks, chromosome aberrations, and cell survival for low- and high-LET radiation particles using TOPAS-nBio and MEDRAS
The increasing sophistication of Monte Carlo (MC)-based simulations, such as TOPAS-nBio for radiation track structure and DNA damage, and MEDRAS-MC for subsequent DNA repair and cell survival, has ushered in an era of in-silico single-cell radiobiology. However, these simulations remain computationally prohibitive. In this study, we introduce a novel method that significantly accelerates the integrated simulation process for in-silico single-cell radiobiology. Our approach centers on pre-calculating and constructing a single-particle-track (SPT) standard DNA damage (SDD) data library using TOPAS-nBio. Each SPT-SDD data entry in this library records the positions of various DNA damage types (e.g., base damage, single-strand breaks, and double-strand breaks) produced by a single particle track. The comprehensive library contains a massive amount of SPT-SDD data entries, covering a broad range of particle energies. This data library functions as a look-up table, allowing for rapid assembly of DNA damage data for any desired dose level. This is achieved by randomly fetching and superimposing many SPT-SDD data entries from the pre-calculated library. The resulting “composite” SDD data file then serves as input for MEDRAS-MC to simulate and compute DNA damage outcomes, including chromosome aberrations and cell lethality for each individual cell. Furthermore, "timestamps" can be added to the superimposed data to account for dose rate effects. This work presents the first integrated Monte Carlo framework that bridges track-structure simulation (TOPAS-nBio) with mechanistic repair-misrepair modeling (MEDRAS-MC) to predict chromosome aberrations and cell lethality on a cell-by-cell basis. In this paper, we first describe this novel methodology and then apply it to compute radiation-induced outcomes for three previously reported in vitro experiments. These applications involve 280-kVp X-rays, protons, and alpha particles, covering a broad spectrum of linear energy transfer (LET). Finally, we compare our in silico results with experimental data and provide a detailed discussion of any observed discrepancies.
- 13 May 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (10)
Open AccessEfficient cell-by-cell simulation of DNA double strand breaks, chromosome aberrations, and cell survival for low- and high-LET radiation particles using TOPAS-nBio and MEDRAS
The increasing sophistication of Monte Carlo (MC)-based simulations, such as TOPAS-nBio for radiation track structure and DNA damage, and MEDRAS-MC for subsequent DNA repair and cell survival, has ushered in an era of in-silico single-cell radiobiology. However, these simulations remain computationally prohibitive. In this study, we introduce a novel method that significantly accelerates the integrated simulation process for in-silico single-cell radiobiology. Our approach centers on pre-calculating and constructing a single-particle-track (SPT) standard DNA damage (SDD) data library using TOPAS-nBio. Each SPT-SDD data entry in this library records the positions of various DNA damage types (e.g., base damage, single-strand breaks, and double-strand breaks) produced by a single particle track. The comprehensive library contains a massive amount of SPT-SDD data entries, covering a broad range of particle energies. This data library functions as a look-up table, allowing for rapid assembly of DNA damage data for any desired dose level. This is achieved by randomly fetching and superimposing many SPT-SDD data entries from the pre-calculated library. The resulting “composite” SDD data file then serves as input for MEDRAS-MC to simulate and compute DNA damage outcomes, including chromosome aberrations and cell lethality for each individual cell. Furthermore, "timestamps" can be added to the superimposed data to account for dose rate effects. This work presents the first integrated Monte Carlo framework that bridges track-structure simulation (TOPAS-nBio) with mechanistic repair-misrepair modeling (MEDRAS-MC) to predict chromosome aberrations and cell lethality on a cell-by-cell basis. In this paper, we first describe this novel methodology and then apply it to compute radiation-induced outcomes for three previously reported in vitro experiments. These applications involve 280-kVp X-rays, protons, and alpha particles, covering a broad spectrum of linear energy transfer (LET). Finally, we compare our in silico results with experimental data and provide a detailed discussion of any observed discrepancies.
- Open Access
- 6 December 2023
- Published by Frontiers Media SA in Frontiers in Nuclear Medicine
- Vol. 3, 1284558
A fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data
Introduction: We developed a new method that drastically speeds up radiobiological Monte Carlo radiation-track-structure (MC-RTS) calculations on a cell-by-cell basis.Methods: The technique is based on random sampling and superposition of single-particle track (SPT) standard DNA damage (SDD) files from a “pre-calculated” data library, constructed using the RTS code TOPAS-nBio, with “time stamps” manually added to incorporate dose-rate effects. This time-stamped SDD file can then be input into MEDRAS, a mechanistic kinetic model that calculates various radiation-induced biological endpoints, such as DNA double-strand breaks (DSBs), misrepairs and chromosomal aberrations, and cell death. As a benchmark validation of the approach, we calculated the predicted energy-dependent DSB yield and the ratio of direct-to-total DNA damage, both of which agreed with published in vitro experimental data. We subsequently applied the method to perform a superfast cell-by-cell simulation of an experimental in vitro system consisting of neuroendocrine tumor cells uniformly incubated with 177Lu.Results and discussion: The results for residual DSBs, both at 24 and 48 h post-irradiation, are in line with the published literature values. Our work serves as a proof-of-concept demonstration of the feasibility of a cost-effective “in silico clonogenic cell survival assay” for the computational design and development of radiopharmaceuticals and novel radiotherapy treatments more generally.
- 6 December 2023
- Published by Frontiers Media SA in Frontiers in Nuclear Medicine
- Vol. 3, 1284558
Open AccessA fast Monte Carlo cell-by-cell simulation for radiobiological effects in targeted radionuclide therapy using pre-calculated single-particle track standard DNA damage data
Introduction: We developed a new method that drastically speeds up radiobiological Monte Carlo radiation-track-structure (MC-RTS) calculations on a cell-by-cell basis.Methods: The technique is based on random sampling and superposition of single-particle track (SPT) standard DNA damage (SDD) files from a “pre-calculated” data library, constructed using the RTS code TOPAS-nBio, with “time stamps” manually added to incorporate dose-rate effects. This time-stamped SDD file can then be input into MEDRAS, a mechanistic kinetic model that calculates various radiation-induced biological endpoints, such as DNA double-strand breaks (DSBs), misrepairs and chromosomal aberrations, and cell death. As a benchmark validation of the approach, we calculated the predicted energy-dependent DSB yield and the ratio of direct-to-total DNA damage, both of which agreed with published in vitro experimental data. We subsequently applied the method to perform a superfast cell-by-cell simulation of an experimental in vitro system consisting of neuroendocrine tumor cells uniformly incubated with 177Lu.Results and discussion: The results for residual DSBs, both at 24 and 48 h post-irradiation, are in line with the published literature values. Our work serves as a proof-of-concept demonstration of the feasibility of a cost-effective “in silico clonogenic cell survival assay” for the computational design and development of radiopharmaceuticals and novel radiotherapy treatments more generally.
- 22 April 2020
- Published by Wiley in Medical Physics
- Vol. 47 (8) , 3485-3495
Optimization of hexagonal‐pattern minibeams for spatially fractionated radiotherapy using proton beam scanning
Purpose: In this study, we investigated computationally and experimentally a hexagonal‐pattern array of spatially fractionated proton minibeams produced by proton pencil beam scanning (PBS) technique. Spatial fractionation of dose delivery with millimeter or submillimeter beam size has proven to be a promising approach to significantly increase the normal tissue tolerance. Our goals are to obtain an optimized minibeam design and to show that it is feasible to implement the optimized minibeams at the existing proton clinics.Methods: An optimized minibeam arrangement is one that would produce high peak‐to‐valley dose ratios (PVDRs) in normal tissues and a PVDR approaching unity at the Bragg peak. Using Monte Carlo (MC) code TOPAS we simulated proton pencil beams that mimic those available at the existing proton therapy facilities and obtained a hexagonal‐pattern array of minibeams by collimating the proton pencil beams through the 1–3 mm diameter pinholes of a collimator. We optimized the minibeam design by considering different combinations of parameters including collimator material and thickness (t), center‐to‐center (c‐t‐c) distance, and beam size. The optimized minibeam design was then evaluated for normal tissue sparing against the uniform pencil beam scanning (PBS) by calculating the therapeutic advantage (TA) in terms of cell survival fraction. Verification measurements using radiochromic films were performed at the Emory proton therapy center (EPTC).Results: Optimized hexagonal‐pattern minibeams having PVDRs of >10 at phantom surface and of >3 at depths up to 6 cm were achieved with 2 mm diameter modulated proton minibeams (with proton energies between 120 and 140 MeV) corresponding to a spread‐out‐Bragg‐peak (SOBP) over the depth of 10–14 cm. The results of the film measurements agree with the MC results within 10%. The TA of the 2 mm minibeams against the uniform PBS is >3 from phantom surface to the depth of 5 cm and then smoothly drops to ~1.5 as it approaches the proximal edge of the SOBP. For 2 mm minibeams and 6 mm c‐t‐c distance, we delivered 1.72 Gy at SOBP for 7.2 × 7.2 × 4 cm3 volume in 48 s.Conclusions: We conclude that it is feasible to implement the optimized hexagonal‐pattern 2 mm proton minibeam radiotherapy at the existing proton clinics, because desirable PVDRs and TAs are achievable and the treatment time is reasonable.
- 22 April 2020
- Published by Wiley in Medical Physics
- Vol. 47 (8) , 3485-3495
Optimization of hexagonal‐pattern minibeams for spatially fractionated radiotherapy using proton beam scanning
Purpose: In this study, we investigated computationally and experimentally a hexagonal‐pattern array of spatially fractionated proton minibeams produced by proton pencil beam scanning (PBS) technique. Spatial fractionation of dose delivery with millimeter or submillimeter beam size has proven to be a promising approach to significantly increase the normal tissue tolerance. Our goals are to obtain an optimized minibeam design and to show that it is feasible to implement the optimized minibeams at the existing proton clinics.Methods: An optimized minibeam arrangement is one that would produce high peak‐to‐valley dose ratios (PVDRs) in normal tissues and a PVDR approaching unity at the Bragg peak. Using Monte Carlo (MC) code TOPAS we simulated proton pencil beams that mimic those available at the existing proton therapy facilities and obtained a hexagonal‐pattern array of minibeams by collimating the proton pencil beams through the 1–3 mm diameter pinholes of a collimator. We optimized the minibeam design by considering different combinations of parameters including collimator material and thickness (t), center‐to‐center (c‐t‐c) distance, and beam size. The optimized minibeam design was then evaluated for normal tissue sparing against the uniform pencil beam scanning (PBS) by calculating the therapeutic advantage (TA) in terms of cell survival fraction. Verification measurements using radiochromic films were performed at the Emory proton therapy center (EPTC).Results: Optimized hexagonal‐pattern minibeams having PVDRs of >10 at phantom surface and of >3 at depths up to 6 cm were achieved with 2 mm diameter modulated proton minibeams (with proton energies between 120 and 140 MeV) corresponding to a spread‐out‐Bragg‐peak (SOBP) over the depth of 10–14 cm. The results of the film measurements agree with the MC results within 10%. The TA of the 2 mm minibeams against the uniform PBS is >3 from phantom surface to the depth of 5 cm and then smoothly drops to ~1.5 as it approaches the proximal edge of the SOBP. For 2 mm minibeams and 6 mm c‐t‐c distance, we delivered 1.72 Gy at SOBP for 7.2 × 7.2 × 4 cm3 volume in 48 s.Conclusions: We conclude that it is feasible to implement the optimized hexagonal‐pattern 2 mm proton minibeam radiotherapy at the existing proton clinics, because desirable PVDRs and TAs are achievable and the treatment time is reasonable.
- 1 June 2019
- Published by Elsevier in Physica Medica
- Vol. 62, 140-151
A cell-by-cell Monte Carlo simulation for assessing radiation-induced DNA double strand breaks
- 1 June 2019
- Published by Elsevier in Physica Medica
- Vol. 62, 140-151
A cell-by-cell Monte Carlo simulation for assessing radiation-induced DNA double strand breaks
- 5 October 2016
- Published by Wiley in Medical Physics
- Vol. 43 (11) , 5791-5793
It is appropriate to deliver the didactic lecture components of masters programs in medical physics completely online
- 5 October 2016
- Published by Wiley in Medical Physics
- Vol. 43 (11) , 5791-5793
It is appropriate to deliver the didactic lecture components of masters programs in medical physics completely online
- Open Access
- 24 October 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 212
A retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer
We conducted a retrospective analysis on 884 patients who were diagnosed with esophageal squamous cell carcinoma (ESCC) and treated with either the neutron brachytherapy in combination with external beam radiotherapy (NBT + EBRT) or 3-dimensional conformal radiation therapy (3D-CRT) to determine the differences in efficacy and morbidity between the two treatment groups. The 884 ESCC patients treated with either NBT + EBRT or 3D-CRT between 2002 and 2012 were retrospectively reviewed and analyzed. Multivariable Cox regression was used to compare oncologic outcomes of the two groups of patients in the context of other clinically relevant variables. The acute and chronic toxicities associated with the two groups were compared using Fisher exact and log-rank tests, respectively. Among the 884 patients, 545 received NBT + EBRT and 339 received 3D-CRT (i.e. EBRT-only). The age range is 39–95 years (median 66). The follow-up time range is 3–145 months (median 32). The analysis shows that the NBT + EBRT group has higher overall survival rate and local control rate than that of the 3D-CRT group. The acute toxicity effects were acceptable for both groups of patients with the NBT + EBRT group showing higher rates of leukopenia and thrombocytopenia and the 3D-CRT group showing higher rates on fistula and massive bleeding. The patients treated with NBT + EBRT showed better oncologic outcomes than those treated with 3D-CRT. The toxicity effects were acceptable for both groups with the NBT + EBRT group showing higher rates on the acute effects and the 3D-CRT group showing higher rates on the late effects.
- 24 October 2015
- Published by Springer Nature in Radiation Oncology
- Vol. 10 (1) , 212
Open AccessA retrospective study of californium-252 neutron brachytherapy combined with EBRT versus 3D-CRT in the treatment of esophageal squamous cell cancer
We conducted a retrospective analysis on 884 patients who were diagnosed with esophageal squamous cell carcinoma (ESCC) and treated with either the neutron brachytherapy in combination with external beam radiotherapy (NBT + EBRT) or 3-dimensional conformal radiation therapy (3D-CRT) to determine the differences in efficacy and morbidity between the two treatment groups. The 884 ESCC patients treated with either NBT + EBRT or 3D-CRT between 2002 and 2012 were retrospectively reviewed and analyzed. Multivariable Cox regression was used to compare oncologic outcomes of the two groups of patients in the context of other clinically relevant variables. The acute and chronic toxicities associated with the two groups were compared using Fisher exact and log-rank tests, respectively. Among the 884 patients, 545 received NBT + EBRT and 339 received 3D-CRT (i.e. EBRT-only). The age range is 39–95 years (median 66). The follow-up time range is 3–145 months (median 32). The analysis shows that the NBT + EBRT group has higher overall survival rate and local control rate than that of the 3D-CRT group. The acute toxicity effects were acceptable for both groups of patients with the NBT + EBRT group showing higher rates of leukopenia and thrombocytopenia and the 3D-CRT group showing higher rates on fistula and massive bleeding. The patients treated with NBT + EBRT showed better oncologic outcomes than those treated with 3D-CRT. The toxicity effects were acceptable for both groups with the NBT + EBRT group showing higher rates on the acute effects and the 3D-CRT group showing higher rates on the late effects.
- 1 September 2014
- Published by Elsevier in Brachytherapy
- Vol. 13 (5) , 514-521
Californium-252 neutron brachytherapy combined with external beam radiotherapy for esophageal cancer: Long-term treatment results
- 1 September 2014
- Published by Elsevier in Brachytherapy
- Vol. 13 (5) , 514-521
Californium-252 neutron brachytherapy combined with external beam radiotherapy for esophageal cancer: Long-term treatment results
- 12 June 2013
- Vol. 99 (2013March-) , 172-5
Early-stage esophageal squamous cell carcinoma treated with californium-252 neutron brachytherapy: clinical report on 16 cases
Californium-252 (²⁵²Cf) neutron brachytherapy is a form of high linear energy transfer radiotherapy, which has proven effective when used in combination with external beam radiotherapy to treat intracavitary cancers of the cervix, colon/rectum and esophagus. No study has been reported for treatment of intracavitary cancers with neutron brachytherapy alone. The aim of the study was to observe and analyze the long-term curative effects and complications for early stage thoracic esophageal cancer patients treated with neutron brachytherapy alone. From December 2001 to August 2006, 16 patients of early stage squamous cell carcinoma underwent neutron brachytherapy. The total radiation dose to the reference point was 20-28 Gy-eq in 5 to 7 fractions with 4 Gy-eq/fraction. The 1-, 3-, and 5-year follow-up rates were 100%. The 2-, 3-, 4-, and 5-year survival rates were 100%, 87.5%, 87.5%, and 75%, respectively. The early complication rates for grades 1 and 2 radiation esophagitis were 75% and 25%, respectively. The late complication rates for grades 0 and 1 (according to the RTOG/EORTC standard) were 87.5% and 12.5%, respectively. Barium esophagography after treatments confirmed that the complete response rate was 100%. Fourteen patients were confirmed by endoscopy to have either normal mucosa or inflammation change. Neutron brachytherapy alone was an effective and safe treatment for early stage esophageal squamous cell cancer.
- 12 June 2013
- Vol. 99 (2013March-) , 172-5
Early-stage esophageal squamous cell carcinoma treated with californium-252 neutron brachytherapy: clinical report on 16 cases
Californium-252 (²⁵²Cf) neutron brachytherapy is a form of high linear energy transfer radiotherapy, which has proven effective when used in combination with external beam radiotherapy to treat intracavitary cancers of the cervix, colon/rectum and esophagus. No study has been reported for treatment of intracavitary cancers with neutron brachytherapy alone. The aim of the study was to observe and analyze the long-term curative effects and complications for early stage thoracic esophageal cancer patients treated with neutron brachytherapy alone. From December 2001 to August 2006, 16 patients of early stage squamous cell carcinoma underwent neutron brachytherapy. The total radiation dose to the reference point was 20-28 Gy-eq in 5 to 7 fractions with 4 Gy-eq/fraction. The 1-, 3-, and 5-year follow-up rates were 100%. The 2-, 3-, 4-, and 5-year survival rates were 100%, 87.5%, 87.5%, and 75%, respectively. The early complication rates for grades 1 and 2 radiation esophagitis were 75% and 25%, respectively. The late complication rates for grades 0 and 1 (according to the RTOG/EORTC standard) were 87.5% and 12.5%, respectively. Barium esophagography after treatments confirmed that the complete response rate was 100%. Fourteen patients were confirmed by endoscopy to have either normal mucosa or inflammation change. Neutron brachytherapy alone was an effective and safe treatment for early stage esophageal squamous cell cancer.
- 1 March 2013
- Published by SAGE Publications in Tumori Journal
- Vol. 99 (2) , 172-175
Early-Stage Esophageal Squamous Cell Carcinoma Treated with Californium-252 Neutron Brachytherapy: Clinical Report on 16 Cases
Aims and background: Californium-252 (252Cf) neutron brachytherapy is a form of high linear energy transfer radiotherapy, which has proven effective when used in combination with external beam radiotherapy to treat intracavitary cancers of the cervix, colon/rectum and esophagus. No study has been reported for treatment of intracavitary cancers with neutron brachytherapy alone. The aim of the study was to observe and analyze the long-term curative effects and complications for early stage thoracic esophageal cancer patients treated with neutron brachytherapy alone. Methods: From December 2001 to August 2006, 16 patients of early stage squamous cell carcinoma underwent neutron brachytherapy. The total radiation dose to the reference point was 20–28 Gy-eq in 5 to 7 fractions with 4 Gy-eq/fraction. The 1-, 3-, and 5-year follow-up rates were 100%. Results: The 2-, 3-, 4–, and 5-year survival rates were 100%, 87.5%, 87.5%, and 75%, respectively. The early complication rates for grades 1 and 2 radiation esophagitis were 75% and 25%, respectively. The late complication rates for grades 0 and 1 (according to the RTOG/EORTC standard) were 87.5% and 12.5%, respectively. Barium esophagography after treatments confirmed that the complete response rate was 100%. Fourteen patients were confirmed by endoscopy to have either normal mucosa or inflammation change. Conclusions: Neutron brachytherapy alone was an effective and safe treatment for early stage esophageal squamous cell cancer.
- 1 March 2013
- Published by SAGE Publications in Tumori Journal
- Vol. 99 (2) , 172-175
Early-Stage Esophageal Squamous Cell Carcinoma Treated with Californium-252 Neutron Brachytherapy: Clinical Report on 16 Cases
Aims and background: Californium-252 (252Cf) neutron brachytherapy is a form of high linear energy transfer radiotherapy, which has proven effective when used in combination with external beam radiotherapy to treat intracavitary cancers of the cervix, colon/rectum and esophagus. No study has been reported for treatment of intracavitary cancers with neutron brachytherapy alone. The aim of the study was to observe and analyze the long-term curative effects and complications for early stage thoracic esophageal cancer patients treated with neutron brachytherapy alone. Methods: From December 2001 to August 2006, 16 patients of early stage squamous cell carcinoma underwent neutron brachytherapy. The total radiation dose to the reference point was 20–28 Gy-eq in 5 to 7 fractions with 4 Gy-eq/fraction. The 1-, 3-, and 5-year follow-up rates were 100%. Results: The 2-, 3-, 4–, and 5-year survival rates were 100%, 87.5%, 87.5%, and 75%, respectively. The early complication rates for grades 1 and 2 radiation esophagitis were 75% and 25%, respectively. The late complication rates for grades 0 and 1 (according to the RTOG/EORTC standard) were 87.5% and 12.5%, respectively. Barium esophagography after treatments confirmed that the complete response rate was 100%. Fourteen patients were confirmed by endoscopy to have either normal mucosa or inflammation change. Conclusions: Neutron brachytherapy alone was an effective and safe treatment for early stage esophageal squamous cell cancer.
- 1 April 2010
- Published by Elsevier in Mutation Research - Reviews in Mutation Research
- Vol. 704 (1-3) , 175-181
The progress of radiobiological models in modern radiotherapy with emphasis on the uncertainty issue
- 1 April 2010
- Published by Elsevier in Mutation Research - Reviews in Mutation Research
- Vol. 704 (1-3) , 175-181
The progress of radiobiological models in modern radiotherapy with emphasis on the uncertainty issue